Overview

Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients

Status:
Unknown status

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B chronic infection.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cytheris SA

Treatments:

Antiviral Agents
Entecavir
Tenofovir
Vaccines